As summarized in the previous paragraphs, infections constitute a significant complication of treatment with CD3xCD20 BsABs; however, they are still less frequent than infections occurring in plasma cell myeloma (PCM) patients treated with BsABs especially targeting BCMA (B-cell maturation antigen). Here, TNFRSF17 is linked to plasma cell myeloma.